PD-L1 Expression in Non-clear cell Renal Cell Carcinoma

  • Choueiri T
  • Fay A
  • Gray K
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

BACKGROUND: Program Death Ligand-1 (PD-L1) expression in non-clear cell RCC (non-ccRCC) and its association with clinical outcomes are unknown. METHODS: Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from 101 patients with non-ccRCC. PD-L1 expression was evaluated by immunohistochemistry in both tumor cell membrane and tumor infiltrating mononuclear cells (TIMC). PD-L1 tumor positivity was defined as >/=5% tumor cell membrane staining. For PD-L1 expression in TIMC, a combined score based on the extent of infiltrate and percentage of positive cells was used. Baseline clinico-pathological characteristics and outcome data [time to recurrence (TTR) and survival (OS)] were correlated with PD-L1 staining. RESULTS: Among 101 patients, 11 (10.9%) were considered PD-L1+ in tumor cells: 2/36 (5.6%) of chromophobe RCC, 5/50 (10%) of papillary RCC, 3/10 (30%) of Xp11.2 translocation RCC and 1/5 (20%) of collecting duct carcinoma. PD-L1 positivity (PD-L1+) in tumor cells was significantly associated with higher stage (p=0.01) and grade (p=0.03), as well as shorter OS (p

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Authors

  • T K Choueiri

  • A P Fay

  • K P Gray

  • M Callea

  • T H Ho

  • L Albiges

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free